Otsuka inks agreement with Eisai to acquire rights to hematological cancer treatment Dacogen

Otsuka Pharmaceutical Co., Ltd. (Otsuka) has announced an agreement with Eisai Inc. (Eisai), a U.S. subsidiary of Eisai Co., Ltd. to acquire rights to the hematological cancer treatment Dacogen® and to an enzyme inhibitor, E7727.

Purpose and Significance of the Agreement

Otsuka's activities in the area of hematological malignancies began in March 2008 with the promotion of IV Busulfex®, a conditioning agent used prior to hematopoietic stem cell transplantation in patients with chronic myeloid leukemia. Since 2010, Otsuka has co-promoted Sprycel® in a joint venture with Bristol-Myers Squibb for treatment of patients in Japan, the U.S. and Europe with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Otsuka also has in phase II clinical trials a prodrug subcutaneous injection of decitabine, SGI-110. With Dacogen®, and potentially in the future with SGI-110 and ASTX727, Otsuka aims to further improve the quality of treatments available to patients with hematological malignancies.

Source:

Otsuka Pharmaceutical Co., Ltd.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
People with blood-related cancers more likely to experience COVID breakthrough infections